| answer text |
<p>The Government has invested over £300 million to secure and scale-up the UK’s manufacturing
capabilities to be able to respond to this pandemic, as well as any future pandemics.
This includes:</p><p>a) Facilities that have come online:</p><ul><li>£65.5 million
for the early manufacture of the University of Oxford/AstraZeneca vaccine;</li><li>£8.75
million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire;</li><li>£8.6
million to the Centre of Process Innovation to develop GMP-ready mRNA manufacturing
capability;</li><li>£4.7 million for skills training through the Advanced Therapies
Skills Training Network, which will be delivered through both virtual and physical
centres; and</li><li>Funding for fill and finish through a contract with Wockhardt
in Wrexham, North Wales, which is currently providing fill and finish capabilities
to the University of Oxford/AstraZeneca vaccine.</li></ul><p>b) Facilities that will
come online later this year, to help provide longer-term UK capacity:</p><ul><li>£140.6
million to accelerate the completion and expanded role of the Vaccines Manufacturing
Innovation Centre in Oxfordshire;</li><li>£127 million for the Cell and Gene Therapy
Catapult in Braintree, Essex; and</li><li>Funding for the expansion of the Valneva
factory in Livingston, Scotland.</li></ul>
|
|
